Clinical Trial: A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281079) titled 'A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome' on Nov. 13.

Brief Summary: This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.

Study Start Date: Nov. 12

Study Type: INTERVENTIONAL

Condition: Phelan-McDermid Syndrome

Intervention: DRUG: NNZ-2591

The study drug will be administered twice daily orally.

DRUG: Placebo

The study drug will be administered twice daily orally.

Recruitment Status: RECRUITING

Sponsor: Neuren Phar...